American Academy of Dermatology

FDA Implements AADA's iPLEDGE Recommendations

Retrieved on: 
Tuesday, December 5, 2023
Workgroup, Isotretinoin, Dermatology, American Academy, Patient, REMS, Pregnancy, American Academy of Dermatology, FDA, Data collection, AAD, Hearing, Letter, AADA, FAAD, Pharmaceutical industry, Birth control, Medical device, MD

WASHINGTON, Dec. 5, 2023 /PRNewswire/ -- The FDA agreed to require important American Academy of Dermatology's (AAD) recommended changes to the iPLEDGE program that will alleviate administrative burdens for dermatologists.

Key Points: 
  • "The FDA supported the AADA's critical recommendations that include allowing for continued use of at home and non-CLIA pregnancy tests."
  • In 2023, 300 AAD members sent about 600 messages to the FDA urging changes to iPLEDGE REMS Program.
  • These grassroots efforts, combined with AAD's strong advocacy led by its iPLEDGE Workgroup, including testifying during an FDA hearing in March, convinced the FDA to require modifications to the iPLEDGE REMS to minimize burdens on patients and dermatologists while maintaining the safe use of isotretinoin.
  • The AAD has been fighting for these changes since 2021, when the FDA transitioned to a new iPLEDGE platform that malfunctioned and disrupted treatment for many patients.

Veradermics Co-Founder and CEO, Reid Waldman, Named to the 2023 Forbes "30 Under 30" Healthcare List

Retrieved on: 
Wednesday, November 29, 2023
Entrepreneurship, Wart, Clinical trial, Medicine, American Academy, Cedars-Sinai Medical Center, University, Pattern hair loss, Atopic dermatitis, Therapy, American Academy of Dermatology, Health care, Health, Skin, Physician, Publication, Hair loss, Molluscum contagiosum, Pharmaceutical industry, Dermatology

NEW HAVEN, Conn., Nov. 29, 2023 /PRNewswire-PRWeb/ -- Veradermics Inc., a clinical-stage medical dermatology company developing new therapeutics for a range of skin and hair loss conditions, today announced that Co-Founder and CEO, Reid Waldman, has been included in the 2023 Forbes "30 Under 30" Healthcare list, recognizing leading scientists and entrepreneurs developing innovative solutions that address some of healthcare's biggest challenges.

Key Points: 
  • Two products of which Waldman is an inventor, including an immune stimulatory microarray for warts and a non-hormonal oral therapeutic for androgenetic alopecia, are currently in clinical trials.
  • In a significant milestone, the company recently announced the dosing of the first patient in a clinical trial for its non-hormonal oral therapeutic for pattern hair loss.
  • In addition to the two therapeutics currently in trials for warts and pattern hair loss, Veradermics pipeline also includes candidates targeting alopecia areata, atopic dermatitis, and molluscum contagiosum.
  • The company expects to advance these additional product candidates into the clinic in 2024.

Removery Announces Chief Medical Officer and New Chair of Clinical Advisory Board

Retrieved on: 
Wednesday, October 11, 2023
Steps, United States Air Force Scientific Advisory Board, Internal medicine, Cosmeceutical, Allergy, Regenerative medicine, MD, Society, Health, Surgery, American Academy of Dermatology, Laser, Skin, Advisory board, Research, Medical device, Nursing, Mineral oil, Dermatology

AUSTIN, Texas, Oct. 11, 2023 /PRNewswire-PRWeb/ -- Removery, the world's largest tattoo removal experts, announced today that Dr. Joshua Weitz, MD will be joining Removery's executive team as Chief Medical Officer and Dr. William Kwan will be stepping up as chair of the Clinical Advisory Board.

Key Points: 
  • Dr. Weitz is a founding member of the Removery Clinical Advisory Board and has previously served as an advisor to the team.
  • As Chief Medical Officer, Dr. Weitz will lead Removery's renowned clinical team in delivering excellence as the authority in the tattoo removal industry and provide safe, effective and optimal laser tattoo removal treatments.
  • Dr. William Kwan, who has served on Removery's Clinical Advisory Board for the past 2 years, is now the board's chair.
  • "We are looking forward to continuing to evolve the clinical and medical sphere of tattoo removal and we are thankful for our outgoing chair member, Thomas Barrows, MD, for his time as the Chair of the Clinical Advisory Board of Removery.

The Inner Circle Acknowledges, Jason Chouake as a Most Trusted Healthcare Professional for his contributions to the field of Dermatology

Retrieved on: 
Friday, September 29, 2023
American Academy of Dermatology, Travel, Physician, Education, Dermatitis, Skin cancer, American Academy, Moles, Multimedia, Inner circle, Psoriasis, Yeshiva University, Montefiore, Family, Dermatology

CLIFFSIDE PARK, N.J., Sept. 29, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Jason Chouake is acknowledged as a Most Trusted Healthcare Professional for his contributions to the field of Dermatology.

Key Points: 
  • CLIFFSIDE PARK, N.J., Sept. 29, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Jason Chouake is acknowledged as a Most Trusted Healthcare Professional for his contributions to the field of Dermatology.
  • He later earned a Medical Doctor degree from Albert Einstein School of Medicine, Montefiore, where he also completed his residency in Dermatology.
  • A fellow of the American Academy of Dermatology, the doctor has extensive experience in Skin Cancer and Excision; Cosmetic Skin Procedures; and Skin Conditions.
  • Aside from his professional pursuits, Dr. Chouake likes to spend time with his family and travel.

Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, September 12, 2023
Insurance, Maintenance, Asthma, American Academy of Dermatology, Week, Center for Drug Evaluation and Research, New Drug Application, NDA, American Academy, Atopic dermatitis, Research, CNTB, Polyp (medicine), USD, Ulcerative colitis, Accounting, Congress, UC, Patient, AAD, Spirometry, Investment, SAN, CDE, Sinusitis, Entrepreneurship, Cytokine, R, AD, FDA, Type 2 inflammation, FEV1, RMB, Safety, Pharmaceutical industry, Vaccine, Medical imaging, Cryptocurrency, Dermatology

SAN DIEGO and TAICANG, China, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today reported financial results for the six months ended June 30, 2023 and provided a business update.

Key Points: 
  • SAN DIEGO and TAICANG, China, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today reported financial results for the six months ended June 30, 2023 and provided a business update.
  • “We also reported positive long-term data from the Phase 2 maintenance period in ulcerative colitis with our other late-stage asset – icanbelimod.
  • There were no new safety signals and icanbelimod continued to be well-tolerated, consistent with observed induction period safety data.
  • Published in July 2023 the pre-clinical data characterizing rademikibart in Nature’s Scientific Reports.

Samsung Bioepis Partners with Sandoz to Commercialize Ustekinumab Biosimilar Candidate

Retrieved on: 
Monday, September 11, 2023
SB5, European Economic Area, Etanercept, SB2, Adalimumab, Pharmacokinetics, Samsung, American Academy, Novartis, Trial of the century, Infliximab, AAD, American Academy of Dermatology, Congress, Safety, Generic drug, Mobile phone, EEA, Ustekinumab

Enters into a commercialization agreement for SB17, ustekinumab biosimilar candidate, in Europe and North America

Key Points: 
  • Enters into a commercialization agreement for SB17, ustekinumab biosimilar candidate, in Europe and North America
    INCHEON, Korea, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. today announced that it has entered into a commercialization agreement with Sandoz for SB17, a proposed biosimilar to Stelarai (ustekinumab), marking a step forward in strengthening access to Samsung Bioepis’ immunology portfolio in the United States (US), Canada, European Economic Area (EEA), Switzerland and United Kingdom (UK).
  • “This agreement is a testament to Samsung Bioepis’ strong track record in the field of immunology, demonstrating a potential value that our biosimilars could deliver for widening access to biologic medicines.” said Sang-Jin Pak, Executive Vice President and Head of Commercial Division, at Samsung Bioepis.
  • SB17, a proposed biosimilar to Stelara (ustekinumab), is Samsung Bioepis’ fourth candidate in its immunology pipeline, following SB4 (etanercept), SB2 (infliximab) and SB5 (adalimumab).
  • Samsung Bioepis has a more than 5-year track record of supplying over 48 million units of immunology biosimilars in nearly 40 markets across the world.

U.S. Dermatology Partners Announces the Opening of St. Joseph, Missouri Office

Retrieved on: 
Tuesday, September 12, 2023
National Register of Historic Places, Travel, American Academy of Dermatology, Kansas City Chiefs, Partner, Dermatitis, Alpha Omega Alpha, Skin cancer, American Academy, Acne, Outreach, Psoriasis, Recreation, Patient, Public key certificate, Architecture, Interstate 29, National Register of Historic Places listings in Dakota County, Minnesota, Interstate Highway System, Barbershop Quartet (health outreach program), Hospital, Dermatology

ST. JOSEPH, Mo., Sept. 12, 2023 /PRNewswire-PRWeb/ -- U.S. Dermatology Partners is pleased to announce the opening of its newest office location in St. Joseph, Missouri. This new location is the latest addition to the organization's Outreach Program which is committed to serving rural and underserved communities. To improve access to professional dermatologic care in rural areas, U.S. Dermatology Partners is launching more than 30 new locations across eight states. These new offices, including the one in St. Joseph, will give patients more convenient access to the care they need and deserve. Beginning September 12th, the office will extend convenient access to dermatology and skin cancer treatments for patients in Andrew and Buchanan Counties.

Key Points: 
  • U.S. Dermatology Partners expands access to dermatology care to patients in Andrew and Buchanan Counties by opening the organization's newest office.
  • ST. JOSEPH, Mo., Sept. 12, 2023 /PRNewswire-PRWeb/ -- U.S. Dermatology Partners is pleased to announce the opening of its newest office location in St. Joseph, Missouri .
  • To improve access to professional dermatologic care in rural areas, U.S. Dermatology Partners is launching more than 30 new locations across eight states.
  • The St. Joseph office is conveniently located at 3107 Frederick Ave., #B, St. Joseph, Missouri, 64506.

Skin cancer screening guidelines can seem confusing – three skin cancer researchers explain when to consider getting checked

Retrieved on: 
Friday, August 11, 2023
People, Melanoma, Survivor, Systematic review, Conversation, American Academy of Dermatology, Awareness, Dermis, Bed, Skin, Neoplasm, Survival, Epidermis, Skin cancer, Light, Cancer, Ultraviolet, Immunity, SPF, Moles, Sunscreen, Prognosis, Clothing, Research, American Academy, Inflammation, Basal-cell carcinoma, Tanning, CDC, Death, Incidence, UPF, Population, Patient, UV, Risk, Overdiagnosis, Carcinoma, Korea Disease Control and Prevention Agency, Lip, Observation, Skin Cancer Foundation, Diagnosis, Program, Center, Sun protection, Burns, Immunodeficiency, Health, Metastasis, Medical imaging, Vaccine, Birth control, Dietary supplement, Cosmetics, Leather, Personal protective equipment, Dermatology

And public health messaging around when and how to be screened for skin cancer has become somewhat confusing.

Key Points: 
  • And public health messaging around when and how to be screened for skin cancer has become somewhat confusing.
  • In April 2023, the U.S. Preventive Services Task Force, an independent national panel of science experts, provided updated recommendations on skin cancer screening following a systematic review of existing research.
  • The task force concluded that the evidence does not support annual widespread skin screening of adolescents and adults, but that catching cancers at the earliest stages reduces the risk of death from skin cancer.

How common is skin cancer in the US?

    • Skin cancer affects about 6 million Americans yearly, according to the Centers for Disease Control and Prevention.
    • Basal cell carcinoma and squamous cell carcinoma – collectively known as keratinocyte cancers – account for more than 97% of skin cancer cases, but invasive melanomas cause the most deaths.
    • Unlike normal cells, skin cancer cells grow without constraints, acquiring the ability to invade down into the dermis.

What are the main causes of skin cancer?

    • Both light- and dark-skinned people can get skin cancer, but light-skinned individuals have a greater risk.
    • Those with light skin, light or red hair, or with numerous moles, are more susceptible to skin damage and severe burns by ultraviolet rays.
    • People who use tanning beds are at a higher risk of skin damage and skin cancers.

What is the debate behind screening?

    • The ongoing debate revolves around whether more screening reduces the death toll from melanoma.
    • This increase may be due in part to more emphasis on early detection.
    • More melanomas have been found, particularly those identified at the earliest stage, also known as stage 0 or melanoma in situ.

What did the task force base its new recommendations on?

    • The task force reviewed current and past data on the major types of skin cancers.
    • The expert panel relied in part on the results of a large public skin cancer screening program in Germany.

When should you get a skin exam?

    • Luckily, there are many online guides on detecting suspicious skin lesions.
    • Whenever you have a concern about a spot on your skin, seek medical advice.
    • This includes those who are older or susceptible to getting skin cancers, skin cancer survivors and immunocompromised people like organ transplant recipients.
    • In response, nonprofits like the American Academy of Dermatology, the Skin Cancer Foundation and The Sun Bus provide resources for free exams.

How can you minimize the risk of skin cancer?


    Strategies that limit UV exposure will reduce skin cancer risk. This includes avoiding sunburns by:
    • Apply these products 15-20 minutes before heading out into the sun and reapply every two hours.
    • UV light is most intense between the hours of 10 a.m. to 4 p.m.
    • These measures can keep your skin healthy into your golden years by reducing skin aging and cancer caused by ultraviolet light.
    • Neil Box receives funding from the National Institutes of Health and the American Skin Association.

AMERICAN ACADEMY OF DERMATOLOGY: HOW TO CARE FOR AN INJURED NAIL

Retrieved on: 
Tuesday, July 25, 2023
Infection, Heart, Hair, American Academy of Dermatology, Arm, Bleeding, Accident, Nail, American Academy, Leg, Doctor of Philosophy, FAAD, Patient, AAD, Swelling, Paracetamol, Water, Weill Cornell Medicine, Ibuprofen, Bacteria, Shoe, Health, Skin, Injury, Petroleum jelly, Cosmetics

ROSEMONT, Ill., July 25, 2023 /PRNewswire/ -- It's easy to injure a nail by slamming a finger in a car door, wearing the wrong shoes, or getting a sports injury. While these common accidents can happen throughout our life, a board-certified dermatologist from the American Academy of Dermatology (AAD) is providing tips to help you treat an injured nail at home, so you're prepared if it happens.

Key Points: 
  • While these common accidents can happen throughout our life, a board-certified dermatologist from the American Academy of Dermatology (AAD) is providing tips to help you treat an injured nail at home, so you're prepared if it happens.
  • If you do get a nail injury, Dr. Lipner and the AAD recommend these tips:
    Treat your wound.
  • Prop the arm or leg with an injured nail on pillows so the nail is higher than your heart.
  • These tips are demonstrated in " How to Care for an Injured Nail ," a video posted to the AAD website and YouTube channel .

Olansky Dermatology & Aesthetics welcomes Dr. Erica S. Tarabadkar to acclaimed roster

Retrieved on: 
Thursday, July 20, 2023
University, Mohs surgery, Aesthetics, Skin cancer, Research, Virginia Mason Medical Center, Alpha Omega Alpha, AOA, Psoriasis, American Medical Association, Morehouse School of Medicine, Medical Society, Patient, The International League of Dermatological Societies, University of Washington School of Medicine, American Academy of Dermatology, Malignancy, Family, Skin, Veterinary medicine, Dermatology, Medicine

ATLANTA, July 20, 2023 /PRNewswire-PRWeb/ -- Olansky Dermatology & Aesthetics –Georgia's top-rated dermatology practice– welcomes Dr. Erica S. Tarabadkar, a board-certified dermatologist. With the addition of Dr. Tarabadkar to Olansky Dermatology & Aesthetics' acclaimed team, patients can continue to choose Olansky Dermatology & Aesthetics for innovative and personalized skincare treatment.

Key Points: 
  • ATLANTA, July 20, 2023 /PRNewswire-PRWeb/ -- Olansky Dermatology & Aesthetics –Georgia's top-rated dermatology practice– welcomes Dr. Erica S. Tarabadkar, a board-certified dermatologist.
  • With the addition of Dr. Tarabadkar to Olansky Dermatology & Aesthetics' acclaimed team, patients can continue to choose Olansky Dermatology & Aesthetics for innovative and personalized skincare treatment.
  • "Our patient community is fortunate to have Dr. Tarabadkar join us, as she offers both her expertise and compassionate care," says Dr. Jodi Ganz, managing physician partner at Olansky Dermatology & Aesthetics.
  • Olansky Dermatology and Aesthetics offers convenient access to high-quality full service dermatology from the comfort of your own home.